Regen BioPharma, Inc. (OTCMKTS:RGBP) Short Interest Update

Regen BioPharma, Inc. (OTCMKTS:RGBP) was the target of a large growth in short interest in the month of July. As of July 15th, there was short interest totalling 6,300 shares, a growth of 1,160.0% from the June 30th total of 500 shares. Based on an average trading volume of 47,500 shares, the short-interest ratio is currently 0.1 days.

Regen BioPharma Stock Up 26.6 %

Shares of RGBP opened at 0.38 on Thursday. Regen BioPharma has a fifty-two week low of 0.26 and a fifty-two week high of 2.02. The firm’s 50 day moving average price is 0.44 and its 200 day moving average price is 0.32.

Regen BioPharma Company Profile

Regen BioPharma, Inc focuses on the development of regenerative medical applications in the United States. It engages in identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications, and immune cell suppression for autoimmune disease. The company is involved in the development of its products, and therapies, including HemaXellarate, a cellular therapeutic product of autologous stromal vascular fraction derived from adipose tissue; dCellVax, an autologous dendritic cell which is treated with an siRNA inhibitor of indoleamine-2,3-dioxygenase; tCellVax which is treated with siRNA to inhibit NR2F6 and the cells re-infused to the patient; DiffronC, uses proprietary siRNA in vivo to inhibit cancer growth and activate T cells; and DuroCAR comprising of CAR-T cells which is treated with an shRNA targeting the gene NR2F6.